News
Novo Nordisk Has Ended Its Wegovy Deal With Hims & Hers: Here's What Investors Need to Know
Novo Nordisk alleged that Hims & Hers is putting patient safety at risk by selling compounded versions of Wegovy. Novo's ending of its deal with Hims & Hers jeopardizes the healthcare platform's goal to lead the weight loss market.
9hon MSN
Hims & Hers Health’s stock booked record losses Monday after Novo Nordisk, maker of the weight-loss drug Wegovy, said it was ...
Hims & Hers delivered record Q1 results and expanded into Europe with the Zava acquisition. Click here to see why HIMS stock ...
Novo Nordisk has ended a partnership with telehealth company Him & Hers, after launching the collaboration less than two ...
The loss of its ability to sell Wegovy is a significant hit to Hims & Hers' business. The massive drop today in its stock ...
Stocks were rising Monday, shrugging off Iran’s attack on a U.S. base in Qatar after the U.S. struck Iranian nuclear sites ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback